222 related articles for article (PubMed ID: 35632574)
21. COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy.
Stufano A; Buonvino N; Trombetta CM; Pontrelli D; Marchi S; Lobefaro G; De Benedictis L; Lorusso E; Carofiglio MT; Vasinioti VI; Montomoli E; Decaro N; Lovreglio P
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891301
[TBL] [Abstract][Full Text] [Related]
22. Omicron Breakthrough Infection After Heterologous Prime-Boost Vaccination Induces a Vigorous Antibody Response.
Varese A; Mazzitelli B; Erra Díaz F; Kjolhede MV; Ojeda D; Vellicce A; Arto P; Cicero C; Pascowsky M; Figueras L; Broese B; Dávila R; Zarlenga R; Rivelli F; Verruno C; Silenzi V; Beltrán I; Gamarnik A; Ceballos A; Zala C; Badolati A; Geffner J
J Infect Dis; 2022 Nov; 226(10):1717-1720. PubMed ID: 35723970
[TBL] [Abstract][Full Text] [Related]
23. A Seroprevalence Study on Residents in a Senior Care Facility with Breakthrough SARS-CoV-2 Omicron Infection.
Kim HM; Lee EJ; O SW; Choi YJ; Lee H; Oh SJ; Kim JM; Park AK; Kim JA; Lee CY; Kim JM; Park H; Park YJ; Yu JH; Kim EY; Ko HP; Kim EJ
Viral Immunol; 2023 Apr; 36(3):203-208. PubMed ID: 36951666
[TBL] [Abstract][Full Text] [Related]
24. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
Zou J; Xia H; Xie X; Kurhade C; Machado RRG; Weaver SC; Ren P; Shi PY
Nat Commun; 2022 Feb; 13(1):852. PubMed ID: 35140233
[TBL] [Abstract][Full Text] [Related]
25. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals.
Vilibic-Cavlek T; Stevanovic V; Kovac S; Borko E; Bogdanic M; Miletic G; Hruskar Z; Ferenc T; Coric I; Vujica Ferenc M; Milasincic L; Antolasic L; Barbic L
Antibodies (Basel); 2023 Sep; 12(4):. PubMed ID: 37873858
[TBL] [Abstract][Full Text] [Related]
27. The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics.
Yap J; Kayda I; Asamoah-Boaheng M; Haig S; Kirkham T; Cheskes S; Demers P; Goldfarb D; Grunau BE
Access Microbiol; 2023; 5(11):. PubMed ID: 38074102
[TBL] [Abstract][Full Text] [Related]
28. Correlation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals.
Chowdhury SH; Riley S; Mikolajczyk R; Smith L; Suresh L; Jacobs A
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992501
[TBL] [Abstract][Full Text] [Related]
29. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.
Godkov MA; Ogarkova DA; Gushchin VA; Kleymenov DA; Mazunina EP; Bykonia EN; Pochtovyi AA; Shustov VV; Shcheblyakov DV; Komarov AG; Tsibin AN; Zlobin VI; Logunov DY; Gintsburg AL
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679936
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
[TBL] [Abstract][Full Text] [Related]
31. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
[TBL] [Abstract][Full Text] [Related]
32. BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.
Kaznadzey A; Tutukina M; Bessonova T; Kireeva M; Mazo I
Front Immunol; 2022; 13():797918. PubMed ID: 35493476
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
Suntronwong N; Yorsaeng R; Puenpa J; Auphimai C; Thongmee T; Vichaiwattana P; Kanokudom S; Duangchinda T; Chantima W; Pakchotanon P; Assawakosri S; Nilyanimit P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335023
[TBL] [Abstract][Full Text] [Related]
34. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients.
Fu J; Shen X; Anderson M; Stec M; Petratos T; Cloherty G; Montefiori DC; Landay A; Moy JN
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423000
[TBL] [Abstract][Full Text] [Related]
35. Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon
Byazrova MG; Kulemzin SV; Astakhova EA; Belovezhets TN; Efimov GA; Chikaev AN; Kolotygin IO; Gorchakov AA; Taranin AV; Filatov AV
Front Immunol; 2022; 13():840707. PubMed ID: 35280987
[TBL] [Abstract][Full Text] [Related]
36. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees.
Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Franchi F; Cusi MG
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632563
[TBL] [Abstract][Full Text] [Related]
37. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.
Doria-Rose NA; Shen X; Schmidt SD; O'Dell S; McDanal C; Feng W; Tong J; Eaton A; Maglinao M; Tang H; Manning KE; Edara VV; Lai L; Ellis M; Moore K; Floyd K; Foster SL; Atmar RL; Lyke KE; Zhou T; Wang L; Zhang Y; Gaudinski MR; Black WP; Gordon I; Guech M; Ledgerwood JE; Misasi JN; Widge A; Roberts PC; Beigel J; Korber B; Pajon R; Mascola JR; Suthar MS; Montefiori DC
medRxiv; 2021 Dec; ():. PubMed ID: 34931200
[TBL] [Abstract][Full Text] [Related]
38. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
39. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
40. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
Khong KW; Liu D; Leung KY; Lu L; Lam HY; Chen L; Chan PC; Lam HM; Xie X; Zhang R; Fan Y; To KK; Chen H; Yuen KY; Chan KH; Hung IF
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
